1. Wratil PR, Stern M, Priller A, Muenchhoff M, Daechert C, Mairhofer H, Krebs S, Fingerle V, Graf A, Steininger P, Blum H, Hornung V, Liebl B, Überla K, Prelog M, Knolle PA*, Keppler OT*, Protzer U*. Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. Nature Medicine 2022, 28: 496-503. 10.1038/s41591-022-01715-4 *equal contribution2. Koerber N, Priller A, Yazici S, Bauer T, Winter C, Ruland J, Gerhard M, Haller B, Christa C, Zelger O, Roggendorf H, Halle M, Erber J, Lingor P, Keppler O, Zehn D, Protzer U, Knolle PA. Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents. Nature Communications 2022, 13: 153. 10.1038/s41467-021-27649-y3. Dudek M, Pfister D, Donakonda S, Tilg H, Thimme R, Bottler T, Tacke F, Dufour JF, Haller D, Murray PJ, Heeren R, Zehn D, Böttcher JP, Heikenwälder M, Knolle PA. Auto-aggressive CXCR6(+) CD8 T cells cause liver immune pathology in NASH. Nature 2021, 592: 444-449. 10.1038/s41586-021-03233-84. Pfister D, Nunez NG, Pinyol R, Govaere O, Djouder N, Wolter K, Zender L, Marche PN, Decaens T, Pinato DJ, Rad R, Mertens JC, Weber A, Unger K, Meissner F, Roth S, Jilkova ZM, Claassen M, Anstee QM, Amit I, Knolle PA, Becher B, Llovet JM, Heikenwälder M. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 2021, 592: 450-456. 10.1038/s41586-021-03362-05. Baumann T, Dunkel A, Schmid C, Schmitt S, Misgeld T, Zischka H, Murray PJ, Heine A, Heikenwälder M, Korn T, Dawid C, Hofmann T, Knolle PA*, Höchst B*. Regulatory myeloid cells paralyze T cells through cell–cell transfer of the metabolite methylglyoxal. Nature Immunology 2020, 21: 555-566. 10.1038/s41590-020-0666-9 *equal contribution6. Welz M, Eickhoff S, Abdullah Z, Demetris AJ, Akhlaghi H, Anton M, Manske K, Zehn D, Nieswandt B, Kurts C, Trapani JA, Knolle PA*, Wohlleber D*, Kastenmuller W*. Perforin inhibition protects from lethal endothelial damage during fulminant viral hepatitis. Nature Communications. 2018, 9: 4805. 10.1038/s41467-018-07213-x *equal contribution7. Beyer M, Abdullah Z, Chemnitz JM, Maisel D, Heikenwalder M, Fatkenheuer G, Lang PA, Hartmann P, Knolle PA*, Schultze JL*. Tumor-necrosis factor impairs CD4(+) T cell-mediated immunological control in chronic viral infection. Nature Immunology. 2016, 17: 593-603. 10.1038/ni.3399 *equal contribution8. Huang LR, Wohlleber D, Schmitt E, Garbi N, Croft M, Kurts C, Kubes P, Protzer U, Heikenwalder M, Knolle PA. Intrahepatic myeloid-cell aggregates enable local proliferation of CD8(+) T cells and successful immunotherapy against chronic viral liver infection. Nature Immunology. 2013, 14: 574-583. 10.1038/ni.25739. Burgdorf S, Kautz A, Bohnert V, Knolle PA, Kurts C. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science 2007, 316: 612-616. 10.1126/science.113797110. Limmer A, Ohl J, Kurts C, Ljunggren HG, Reiss Y, Groettrup M, Momburg F, Arnold B, Knolle PA. Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nature Medicine 2000, 6: 1348-1354. https://doir.org:10.1038/82161